Shopping Cart
Remove All
Your shopping cart is currently empty
IRBM-Z-2
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T219082 Copy Product Info
🥰Excellent
IRBM-Z-2 is a non-competitive, orally active inhibitor of the Zika virus (ZIKV) NS2B-NS3 protease, with IC50 values of 0.04 μM for the wild-type and 3.1 μM for the I156T mutant strain. It shows broad-spectrum antiviral potential against flaviviruses, with IC50 values of 2.1 μM for Dengue virus 2 (DENV2) and 0.09 μM for West Nile virus (WNV) NS2B-NS3 proteases. Additionally, IRBM-Z-1 inhibits Zika virus replication and alleviates virus-induced cytopathic effects, making it useful for studies related to ZIKV infection.
IRBM-Z-2
Cas No. 3014840-61-7
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | IRBM-Z-2 is a non-competitive, orally active inhibitor of the Zika virus (ZIKV) NS2B-NS3 protease, with IC50 values of 0.04 μM for the wild-type and 3.1 μM for the I156T mutant strain. It shows broad-spectrum antiviral potential against flaviviruses, with IC50 values of 2.1 μM for Dengue virus 2 (DENV2) and 0.09 μM for West Nile virus (WNV) NS2B-NS3 proteases. Additionally, IRBM-Z-1 inhibits Zika virus replication and alleviates virus-induced cytopathic effects, making it useful for studies related to ZIKV infection. |
| In vitro | IRBM-Z-2 effectively inhibits the activity of the DENV2 NS2B-NS3 T156I mutant protease in biochemical assays with an IC50 of 0.4 μM, demonstrating greater potency than the wild-type protease. IRBM-Z-2 (72 h) strongly suppresses wild-type Zika virus (ZIKV) replicon replication in Vero cells, achieving an EC50 of 0.03 μM without observed cytotoxicity up to 32 μM. It also inhibits the ZIKV I156T mutant replicon in Vero cells with an EC50 of 0.79 μM, exhibiting reduced efficacy compared to the wild-type, and shows no cytotoxicity up to 32 μM concentration. Additionally, IRBM-Z-2 (72 h) impedes West Nile virus (WNV) replicon replication in Vero cells with an EC50 of 0.31 μM and is non-cytotoxic at concentrations as high as 32 μM. IRBM-Z-2 (6 days) strongly curtails ZIKV PRVABC59 strain-induced cytopathic effects (CPE) in BHK-21 cells, possessing an EC50 of 0.016 μM with no cytotoxicity up to 37.9 μM. Furthermore, IRBM-Z-2 (48 h) hinders ZIKV Padova and H/PF/2013 strains in HuH-7 cells, with apparent IC50 values between 6 to 20 nM and no detectable cytotoxicity at tested concentrations. It also inhibits the CPE induced by West Nile virus Kern 515 strain in Vero76 cells, with an EC50 of 1.0 μM and no cytotoxicity observed up to 50 μM. |
| In vivo | IRBM-Z-2, administered intraperitoneally at 100 mg/kg once daily for 5 days, can reduce the serum viral load of ZIKV by up to 4.5 log 10 in AG129 mice, and completely prevent ZIKV-induced weight loss. When given orally at the same dose twice daily for 14 days, it can reduce the serum viral load of ZIKV in AG129 mice to undetectable levels by the 5th day, prevent weight loss caused by ZIKV, and achieve 100% survival in mice. |
| Molecular Weight | 469.42 |
| Formula | C22H18F3N7O2 |
| Cas No. | 3014840-61-7 |
| Smiles | O=C([N-]C=1ON=[N+](C1)CC=2N=CC(=CC2)C3=C(N=CN=C3C)C)NC4=CC=CC(=C4)C(F)(F)F |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: IRBM-Z-2 in vivo | IRBM-Z-2 in vitro | IRBM-Z-2 formula | IRBM-Z-2 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.